Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion type Assertion NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_head.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion description "[The long-term benefits of a finite course of interferon ? (IFN) therapy include a sustained and cumulative response, as well as a reduction in the progression of fibrosis and in the development of cirrhosis and/or HCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion evidence source_evidence_literature NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion SIO_000772 23286854 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion wasDerivedFrom befree-20140225 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.
- NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_assertion wasGeneratedBy ECO_0000203 NP184531.RAcOrueFK55YiR2v6NksjZHk4sD2BvXRYyX3o2TT_9M-4130_provenance.